查看購物車
  • Simplified Chinese
  • English
  • Japanese
細胞治療技術的全球市場：按產品、製程、細胞類型、應用、最終用戶、地區分類 - 預測至 2029 年
市場調查報告書
商品編碼
1633535

細胞治療技術的全球市場：按產品、製程、細胞類型、應用、最終用戶、地區分類 - 預測至 2029 年

Cell Therapy Technologies Market by Product, Process, Cell type, Application, End user - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 466 Pages | 訂單完成後即時交付

價格

全球細胞治療技術市場預計將從2024年的40.3億美元成長到2029年的68億美元以上，複合年成長率高達11.0%。

該市場的推動因素包括再生醫學的進步、慢性病盛行率的上升、研發投資的增加以及 CRISPR 等基因編輯工具的創新。生物技術公司和學術機構之間的策略聯盟以及監管支援和政府資助正在支持新型細胞療法的市場發展並推動市場成長。

調查範圍
調查年份 2022-2029
基準年 2023年
預測期 2024-2029
考慮單位 金額（美元）
按細分市場 按產品、工藝、細胞類型、應用、最終用戶、地區
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東/非洲

細胞治療技術市場依細胞類型分為三大類：T 細胞、幹細胞和其他細胞。 T 細胞對於免疫療法（尤其是 CAR-T 療法）的進步至關重要，刺激了 T 細胞工程和可擴展製造方面的大量投資和創新，因此 T 細胞將在 2023 年佔據市場佔有率。 CRISPR 技術的進步、體外部署和「現成的」同種異體細胞解決方案都有助於進一步加速市場供應。

依應用領域，細胞治療技術市場分為癌症、心血管疾病（CVD）、整形外科疾病、自體免疫疾病等。由於全球癌症發病率不斷上升以及對創新標靶治療的需求不斷成長，癌症應用在該領域佔據主導地位。細胞工程、可擴展製造和固體癌新應用的進步進一步增強了該領域的成長潛力。該領域擁有強大的臨床管道，政府措施以及監管部門的核准也大力支持該領域的發展。

從區域來看，市場分為北美、歐洲、亞太地區、拉丁美洲、中東和非洲。到 2023 年，北美將在細胞治療技術市場佔據主導地位，並且在預測期內也可能保持主導地位。北美因其強大的醫療基礎設施、大量的研發投資以及主要市場參與企業的存在而在細胞治療技術市場佔據主導地位。該地區受益於強力的監管支持，FDA 等機構簡化了創新治療方法的核准。慢性病的高盛行率、對個人化醫療不斷成長的需求以及先進的製造設施進一步增強了該地區的優勢。

該報告研究了全球細胞治療技術市場，包括按產品、工藝、細胞類型、應用、最終用戶、地區和參與市場的公司概況分類的趨勢。

目錄

第1章簡介

第2章調查方法

第3章執行摘要

第 4 章重要考察

第5章市場概況

  • 介紹
  • 市場動態
  • 生態系分析
  • 技術分析
  • 價格分析
  • 價值鏈分析
  • 專利分析
  • 貿易分析
  • 2025-2026年重大會議和活動
  • 監管狀況
  • 波特五力分析
  • 主要相關人員和採購標準
  • 投資金籌措場景
  • 影響客戶業務的趨勢/干擾
  • 人工智慧/產生人工智慧對細胞治療技術市場的影響

第6章細胞治療技術市場，依產品

  • 介紹
  • 培養基、血清、試劑
  • 細胞治療設備
  • 系統及軟體
  • 細胞培養容器
  • 細胞工程產品
  • 其他

第7章細胞治療技術市場（依流程）

  • 介紹
  • 細胞處理
  • 細胞保存
  • 過程監控和品管
  • 細胞處理
  • 細胞分佈

第8章細胞治療技術市場（依細胞類型）

  • 介紹
  • T細胞
  • 幹細胞
  • 其他

第9章細胞治療技術市場（按應用）

  • 介紹
  • 癌症
  • 心血管疾病
  • 整形外科疾病
  • 自體免疫疾病
  • 其他

第10章細胞治療技術市場，依最終用戶分類

  • 介紹
  • 生物製藥和生物技術公司
  • 合約研究官、首席行銷官
  • 研究機構
  • 細胞庫

第11章細胞治療技術市場（按地區）

  • 介紹
  • 北美洲
    • 北美宏觀經濟前景
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲宏觀經濟展望
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 亞太宏觀經濟展望
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲
    • 拉丁美洲宏觀經濟展望
    • 巴西
    • 墨西哥
    • 其他
  • 中東
    • 中東宏觀經濟展望
    • 海灣合作理事會國家
    • 其他
  • 非洲
    • 非洲宏觀經濟展望

第12章競爭格局

  • 概述
  • 主要參與企業的策略/優勢
  • 收益分析
  • 市場佔有率分析
  • 企業評估矩陣：主要參與企業，2023
  • 企業評估矩陣：Start-Ups/小型企業，2023 年
  • 公司評價及財務指標
  • 品牌/產品比較
  • 競爭場景

第13章 公司簡介

  • 主要參與企業
    • DANAHER CORPORATION
    • MERCK KGAA
    • THERMO FISHER SCIENTIFIC INC.
    • LONZA
    • SARTORIUS AG
    • AGILENT TECHNOLOGIES, INC.
    • AVANTOR, INC.
    • FRESENIUS SE & CO. KGAA
    • BECTON, DICKINSON AND COMPANY
    • CORNING INCORPORATED
    • TERUMO CORPORATION
    • BIO-TECHNE
    • GENSCRIPT
    • MAXCYTE
    • STEMCELL TECHNOLOGIES
  • 其他公司
    • OXFORD BIOMEDICA PLC
    • ROOSTERBIO, INC.
    • TRAKCEL
    • L7 INFORMATICS, INC.
    • MILTENYI BIOTEC
    • REPLIGEN CORPORATION
    • MAK SYSTEM
    • ORIGEN BIOMEDICAL, INC.
    • IXCELLS BIOTECHNOLOGIES
    • KORBER AG

第14章附錄

Product Code: BT 6823

The global cell therapy technologies market is projected to surpass USD 6.80 billion in 2029 from USD 4.03 billion in 2024, with a significant CAGR of 11.0%. This market is driven by advancements in regenerative medicine, the rising prevalence of chronic diseases, increasing investments in research and development, and innovations in gene editing tools, such as CRISPR. Regulatory support and government funding, alongside strategic collaborations between biotech firms and academic institutions, are propelling the development of novel cell therapies, subsequently driving the market growth.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD)
SegmentsBy Product, Process, Cell Type, Application and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

"The T cells cell therapy technologies segment accounted for the largest share in 2023."

The cell therapy technologies market is bifurcated into three primary categories based on cell type, that are T cells, stem cells, and other cells. The T cells segment dominated the share of the market in the year 2023 due to being crucial in advancing immunotherapies, especially CAR-T therapies spurring substantial investments and technological innovations in T-cell engineering and scalable manufacturing. Advancements in CRISPR technology, ex vivo expansion, and "off-the-shelf" allogeneic solutions all further help in advancing market offerings.

"By application, the cancer application segment accounted for the largest share in the cell therapy technologies market."

The application segment in the cell therapy technologies market includes cancer, cardiovascular disease (CVD), orthopaedic disorders, autoimmune diseases, and other applications. The cancer application dominated the segment due to increasing prevalence of cancer globally and the rising demand for innovative, targeted therapies. Advancements in cell engineering, scalable manufacturing, and emerging applications in solid tumors further enhance the growth potential of this segment. It possesses a solid clinical pipeline, and the government initiatives are very supportive with regulatory approvals for the growth of the segment.

"North America: the largest share of the cell therapy technologies market"

By region, the market is segment into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. North America dominated the cell therapy technologies market in 2023 and likely continue to be dominant during the forecast period. North America dominates the cell therapy technologies market due to its robust healthcare infrastructure, significant investments in research and development, and the presence of key market players. The region benefits from strong regulatory support, with agencies like the FDA streamlining approvals for innovative therapies. High prevalence of chronic diseases, increasing demand for personalized medicine, and advanced manufacturing facilities further bolster regions dominance.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the cell therapy technologies market.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70% and Demand Side 30%
  • By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Sartorius AG (Germany), Agilent Technologies Inc. (US), Avantor, Inc. (US), Bio-Techne (US), Fresenius SE & Co KGAA (Germany), BD (US), Corning Incorporated (US), Terumo Corporation (Japan), GenScript (US), MaxCyte (US) and STEMCELL Technologies (Canada) are some of the major players operating in the cell therapy technologies market.

Research Coverage:

This research report categorizes the cell therapy technologies market product (media, sera, and reagents; cell engineering products; cell culture vessels; cell therapy equipment; systems & software; and other products), process (cell processing, cell preservation, cell distribution, cell handling, and process monitoring & quality control), cell type (T cells, stem cells, and other cells), application (cancer, cardiovascular disease (CVD), orthopedic disorders, autoimmune diseases, and other applications) end user (biopharmaceutical & biotechnology companies, CROs & CMOs, research institutes, and cell banks) and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the cell therapy technologiess market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the cell therapy technologies market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the cell therapy technologies and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (increased funding and investment in cell therapy, advancements in gene editing technologies, the development of automated cell processing systems, and regulatory support for fast-tracking therapies), restraints (manufacturing and logistical complexity), opportunities (personalized and off-the-shelf cell therapies, integration with digital technologies such as AI & ML) and Challenges (supply chain & cold chain management and manufacturing scalability & quality control).
  • Product Development/Innovation: Detailed insights on maintaining a comprehensive and innovative product portfolio offering for cell therapy technologies.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell therapy technologies market.
  • Competitive Assessment: Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Sartorius AG (Germany), and among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • 2.2.1 MARKET ESTIMATION
    • 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
    • 2.2.3 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
  • 2.3 MARKET GROWTH RATE PROJECTIONS
  • 2.4 DATA TRIANGULATION
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 CELL THERAPY TECHNOLOGIES MARKET OVERVIEW
  • 4.2 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT AND COUNTRY (2023)
  • 4.3 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PRODUCT, 2024 VS. 2029
  • 4.4 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increased funding and investment in cell therapy
      • 5.2.1.2 Advancements in gene editing technologies
      • 5.2.1.3 Development of automated cell processing systems
      • 5.2.1.4 Regulatory support for fast-tracking therapies
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Manufacturing and logistical complexity
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Personalized and off-the-shelf cell therapies
      • 5.2.3.2 Integration with digital technologies such as AI & ML
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Supply chain & cold chain management and manufacturing scalability & quality control
  • 5.3 ECOSYSTEM ANALYSIS
    • 5.3.1 PRODUCT PROVIDERS
    • 5.3.2 END USERS
    • 5.3.3 REGULATORY BODIES
  • 5.4 TECHNOLOGY ANALYSIS
    • 5.4.1 KEY TECHNOLOGIES
      • 5.4.1.1 Magnetic-activated cell sorting
      • 5.4.1.2 Cryopreservation
      • 5.4.1.3 Gene editing technologies
      • 5.4.1.4 Bioprocessing technologies
    • 5.4.2 COMPLEMENTARY TECHNOLOGIES
      • 5.4.2.1 Artificial intelligence and machine learning
      • 5.4.2.2 Biomaterials and scaffolding
      • 5.4.2.3 Automation and scalability
    • 5.4.3 ADJACENT TECHNOLOGIES
      • 5.4.3.1 Nanotechnology
      • 5.4.3.2 Immunotherapy platforms
  • 5.5 PRICING ANALYSIS
    • 5.5.1 AVERAGE SELLING PRICE TREND OF CELL THERAPY PRODUCTS, BY KEY PLAYER, 2022-2024
    • 5.5.2 AVERAGE SELLING PRICE TREND OF CELL THERAPY EQUIPMENT, BY REGION, 2022-2024
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 PATENT ANALYSIS
  • 5.8 TRADE ANALYSIS
    • 5.8.1 IMPORT DATA FOR MACHINES AND APPARATUS FOR ELECTROPLATING, ELECTROLYSIS, OR ELECTROPHORESIS (HS CODE: 854330)
    • 5.8.2 EXPORT DATA FOR MACHINES AND APPARATUS FOR ELECTROPLATING, ELECTROLYSIS, OR ELECTROPHORESIS (HS CODE: 854330)
  • 5.9 KEY CONFERENCES AND EVENTS, 2025-2026
  • 5.10 REGULATORY LANDSCAPE
    • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.10.2 REGULATORY FRAMEWORK
      • 5.10.2.1 North America
      • 5.10.2.2 Europe
      • 5.10.2.3 Asia Pacific
      • 5.10.2.4 Rest of the World
  • 5.11 PORTER'S FIVE FORCES ANALYSIS
    • 5.11.1 THREAT OF NEW ENTRANTS
    • 5.11.2 THREAT OF SUBSTITUTES
    • 5.11.3 BARGAINING POWER OF BUYERS
    • 5.11.4 BARGAINING POWER OF SUPPLIERS
    • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.12.1 KEY STAKEHOLDERS
    • 5.12.2 BUYING CRITERIA
  • 5.13 INVESTMENT & FUNDING SCENARIO
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
  • 5.15 IMPACT OF AI/GEN AI ON CELL THERAPY TECHNOLOGIES MARKET

6 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 MEDIA, SERA, AND REAGENTS
    • 6.2.1 IMPORTANCE OF MEDIA, SERA, AND REAGENTS IN CELL PROCESSING TO DRIVE MARKET
  • 6.3 CELL THERAPY EQUIPMENT
    • 6.3.1 CELL PROCESSING EQUIPMENT
      • 6.3.1.1 Development of automated and closed-system cell processing equipment to accelerate segment growth
    • 6.3.2 SINGLE-USE EQUIPMENT
      • 6.3.2.1 Increasing funding for stem cell therapy to drive market
    • 6.3.3 OTHER CELL THERAPY EQUIPMENT
  • 6.4 SYSTEMS & SOFTWARE
    • 6.4.1 RISING DEMAND FOR CELL THERAPIES TO SUPPORT MARKET GROWTH
  • 6.5 CELL CULTURE VESSELS
    • 6.5.1 RISING R&D AND INVESTMENTS IN CELL-BASED THERAPIES TO DRIVE DEMAND
  • 6.6 CELL ENGINEERING PRODUCTS
    • 6.6.1 AVAILABILITY OF WIDE RANGE OF CELL ENGINEERING PRODUCTS TO SUPPORT MARKET
  • 6.7 OTHER PRODUCTS

7 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS

  • 7.1 INTRODUCTION
  • 7.2 CELL PROCESSING
    • 7.2.1 CELL EXPANSION
      • 7.2.1.1 Rising demand for personalized and regenerative therapies to drive market growth
    • 7.2.2 CELL ISOLATION
      • 7.2.2.1 Rising need for scalable, efficient isolation technologies to drive market
    • 7.2.3 CELL CHARACTERIZATION
      • 7.2.3.1 Increasing demand for high-quality, safe, and effective cell-based therapies to propel growth
    • 7.2.4 CELL COLLECTION
      • 7.2.4.1 Advancements in cell collection technologies to drive market
  • 7.3 CELL PRESERVATION
    • 7.3.1 ADVANCEMENT IN CRYOPRESERVATION TECHNOLOGIES TO DRIVE GROWTH
  • 7.4 PROCESS MONITORING & QUALITY CONTROL
    • 7.4.1 INCREASING DEMAND FOR AUTOMATED QUALITY CONTROL IN CELL THERAPY PRODUCTION TO DRIVE MARKET
  • 7.5 CELL HANDLING
    • 7.5.1 INCREASING DEMAND FOR AUTOMATED, EFFICIENT, AND SCALABLE SOLUTIONS TO DRIVE MARKET GROWTH
  • 7.6 CELL DISTRIBUTION
    • 7.6.1 INCREASED FOCUS ON TRANSPORTATION AND STORAGE TO DRIVE MARKET GROWTH

8 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE

  • 8.1 INTRODUCTION
  • 8.2 T CELLS
    • 8.2.1 RISING RESEARCH ON CAR T-CELL THERAPY TO ACCELERATE GROWTH
  • 8.3 STEM CELLS
    • 8.3.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO PROPEL MARKET
  • 8.4 OTHER CELLS

9 CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
  • 9.2 CANCER
    • 9.2.1 RISING RESEARCH ON CAR T-CELL THERAPY TO ACCELERATE SEGMENT GROWTH
  • 9.3 CARDIOVASCULAR DISEASE
    • 9.3.1 INCREASING FOCUS ON INNOVATIVE CELL THERAPY APPROACHES TO DRIVE MARKET
  • 9.4 ORTHOPEDIC DISORDERS
    • 9.4.1 INCREASING FOCUS ON STEM CELL THERAPY FOR TISSUE REGENERATION TO DRIVE MARKET
  • 9.5 AUTOIMMUNE DISEASES
    • 9.5.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO SUPPORT MARKET GROWTH
  • 9.6 OTHER APPLICATIONS

10 CELL THERAPY TECHNOLOGIES MARKET, BY END USER

  • 10.1 INTRODUCTION
  • 10.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 10.2.1 INCREASING ADOPTION OF INORGANIC GROWTH STRATEGIES BY BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET
  • 10.3 CROS & CMOS
    • 10.3.1 FOCUS ON OUTSOURCING TO DRIVE SEGMENT GROWTH
  • 10.4 RESEARCH INSTITUTES
    • 10.4.1 RISING RESEARCH ACTIVITY TO SUPPORT MARKET GROWTH
  • 10.5 CELL BANKS
    • 10.5.1 INCREASING DEMAND FOR STANDARDIZED CELL LINES TO SUPPORT MARKET GROWTH

11 CELL THERAPY TECHNOLOGIES MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 11.2.2 US
      • 11.2.2.1 US dominates North American cell therapy technologies market
    • 11.2.3 CANADA
      • 11.2.3.1 Increasing government funding to drive adoption of cell therapy instruments
  • 11.3 EUROPE
    • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 11.3.2 GERMANY
      • 11.3.2.1 Germany to hold largest market share
    • 11.3.3 UK
      • 11.3.3.1 Favorable funding & investment scenario to drive market growth
    • 11.3.4 FRANCE
      • 11.3.4.1 Availability of government & private funding to support market growth
    • 11.3.5 ITALY
      • 11.3.5.1 Increasing R&D, public & private investment, and support to offer growth opportunities
    • 11.3.6 SPAIN
      • 11.3.6.1 Advancement in personalized medicine to stimulate market
    • 11.3.7 REST OF EUROPE
  • 11.4 ASIA PACIFIC
    • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 11.4.2 CHINA
      • 11.4.2.1 Increasing R&D expenditure to drive market growth
    • 11.4.3 JAPAN
      • 11.4.3.1 Strong availability of funding to support market growth
    • 11.4.4 INDIA
      • 11.4.4.1 Rising funding programs to drive market
    • 11.4.5 AUSTRALIA
      • 11.4.5.1 Increasing government funding & initiatives to drive market growth
    • 11.4.6 SOUTH KOREA
      • 11.4.6.1 Alliances & investments in research to drive market
    • 11.4.7 REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 11.5.2 BRAZIL
      • 11.5.2.1 Brazil to dominate Latin American market till 2029
    • 11.5.3 MEXICO
      • 11.5.3.1 Strong pharmaceutical industry and increased government support to augment market
    • 11.5.4 REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST
    • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    • 11.6.2 GCC COUNTRIES
      • 11.6.2.1 Saudi Arabia
        • 11.6.2.1.1 Increasing government investments in healthcare and growing pharmaceuticals industry to support market
      • 11.6.2.2 UAE
        • 11.6.2.2.1 Growing R&D expenditure & well-established class infrastructure to drive market
      • 11.6.2.3 Rest of GCC Countries
    • 11.6.3 REST OF MIDDLE EAST
  • 11.7 AFRICA
    • 11.7.1 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET
  • 12.3 REVENUE ANALYSIS
  • 12.4 MARKET SHARE ANALYSIS
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 12.5.5.1 Company footprint
      • 12.5.5.2 Region footprint
      • 12.5.5.3 Product footprint
      • 12.5.5.4 Process footprint
      • 12.5.5.5 Cell type footprint
      • 12.5.5.6 Application footprint
  • 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 RESPONSIVE COMPANIES
    • 12.6.3 DYNAMIC COMPANIES
    • 12.6.4 STARTING BLOCKS
    • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 12.7 COMPANY VALUATION & FINANCIAL METRICS
    • 12.7.1 FINANCIAL METRICS
    • 12.7.2 COMPANY VALUATION
  • 12.8 BRAND/PRODUCT COMPARISON
  • 12.9 COMPETITIVE SCENARIO
    • 12.9.1 PRODUCT LAUNCHES
    • 12.9.2 DEALS
    • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
    • 13.1.1 DANAHER CORPORATION
      • 13.1.1.1 Business overview
      • 13.1.1.2 Products offered
      • 13.1.1.3 Recent developments
        • 13.1.1.3.1 Product launches
        • 13.1.1.3.2 Deals
        • 13.1.1.3.3 Expansions
      • 13.1.1.4 MnM view
        • 13.1.1.4.1 Key strengths
        • 13.1.1.4.2 Strategic choices
        • 13.1.1.4.3 Weaknesses and competitive threats
    • 13.1.2 MERCK KGAA
      • 13.1.2.1 Business overview
      • 13.1.2.2 Products offered
      • 13.1.2.3 Recent developments
        • 13.1.2.3.1 Deals
        • 13.1.2.3.2 Expansions
      • 13.1.2.4 MnM view
        • 13.1.2.4.1 Key strengths
        • 13.1.2.4.2 Strategic choices
        • 13.1.2.4.3 Weaknesses and competitive threats
    • 13.1.3 THERMO FISHER SCIENTIFIC INC.
      • 13.1.3.1 Business overview
      • 13.1.3.2 Products offered
      • 13.1.3.3 Recent developments
        • 13.1.3.3.1 Product launches
        • 13.1.3.3.2 Deals
        • 13.1.3.3.3 Expansions
      • 13.1.3.4 MnM view
        • 13.1.3.4.1 Key strengths
        • 13.1.3.4.2 Strategic choices
        • 13.1.3.4.3 Weaknesses and competitive threats
    • 13.1.4 LONZA
      • 13.1.4.1 Business overview
      • 13.1.4.2 Products offered
      • 13.1.4.3 Recent developments
        • 13.1.4.3.1 Product launches
        • 13.1.4.3.2 Deals
    • 13.1.5 SARTORIUS AG
      • 13.1.5.1 Business overview
      • 13.1.5.2 Products offered
      • 13.1.5.3 Recent developments
        • 13.1.5.3.1 Product launches
        • 13.1.5.3.2 Deals
        • 13.1.5.3.3 Expansions
    • 13.1.6 AGILENT TECHNOLOGIES, INC.
      • 13.1.6.1 Business overview
      • 13.1.6.2 Products offered
      • 13.1.6.3 Recent developments
        • 13.1.6.3.1 Product launches
        • 13.1.6.3.2 Deals
    • 13.1.7 AVANTOR, INC.
      • 13.1.7.1 Business overview
      • 13.1.7.2 Products offered
      • 13.1.7.3 Recent developments
        • 13.1.7.3.1 Deals
    • 13.1.8 FRESENIUS SE & CO. KGAA
      • 13.1.8.1 Business overview
      • 13.1.8.2 Products offered
      • 13.1.8.3 Recent developments
        • 13.1.8.3.1 Deals
    • 13.1.9 BECTON, DICKINSON AND COMPANY
      • 13.1.9.1 Business overview
      • 13.1.9.2 Products offered
      • 13.1.9.3 Recent developments
        • 13.1.9.3.1 Product launches
    • 13.1.10 CORNING INCORPORATED
      • 13.1.10.1 Business overview
      • 13.1.10.2 Products offered
    • 13.1.11 TERUMO CORPORATION
      • 13.1.11.1 Business overview
      • 13.1.11.2 Products offered
      • 13.1.11.3 Recent developments
        • 13.1.11.3.1 Product launches
        • 13.1.11.3.2 Deals
        • 13.1.11.3.3 Expansions
    • 13.1.12 BIO-TECHNE
      • 13.1.12.1 Business overview
      • 13.1.12.2 Products offered
      • 13.1.12.3 Recent developments
        • 13.1.12.3.1 Product launches
        • 13.1.12.3.2 Deals
        • 13.1.12.3.3 Other developments
    • 13.1.13 GENSCRIPT
      • 13.1.13.1 Business overview
      • 13.1.13.2 Products offered
      • 13.1.13.3 Recent developments
        • 13.1.13.3.1 Deals
    • 13.1.14 MAXCYTE
      • 13.1.14.1 Business overview
      • 13.1.14.2 Products offered
      • 13.1.14.3 Recent developments
        • 13.1.14.3.1 Deals
    • 13.1.15 STEMCELL TECHNOLOGIES
      • 13.1.15.1 Business overview
      • 13.1.15.2 Products offered
      • 13.1.15.3 Recent developments
        • 13.1.15.3.1 Product launches
        • 13.1.15.3.2 Deals
  • 13.2 OTHER PLAYERS
    • 13.2.1 OXFORD BIOMEDICA PLC
    • 13.2.2 ROOSTERBIO, INC.
    • 13.2.3 TRAKCEL
    • 13.2.4 L7 INFORMATICS, INC.
    • 13.2.5 MILTENYI BIOTEC
    • 13.2.6 REPLIGEN CORPORATION
    • 13.2.7 MAK SYSTEM
    • 13.2.8 ORIGEN BIOMEDICAL, INC.
    • 13.2.9 IXCELLS BIOTECHNOLOGIES
    • 13.2.10 KORBER AG

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • TABLE 2 CELL THERAPY TECHNOLOGIES MARKET: RISK ANALYSIS
  • TABLE 3 CELL THERAPY TECHNOLOGIES MARKET: KEY PRODUCT PROVIDERS
  • TABLE 4 CELL THERAPY TECHNOLOGIES MARKET: KEY END USERS
  • TABLE 5 CELL THERAPY TECHNOLOGIES MARKET: REGULATORY BODIES
  • TABLE 6 AVERAGE SELLING PRICE TREND OF CELL THERAPY PRODUCTS, BY KEY PLAYER, 2022-2024
  • TABLE 7 AVERAGE SELLING PRICE TREND OF CELL THERAPY EQUIPMENT, BY REGION, 2022-2024
  • TABLE 8 KEY PATENTS IN CELL THERAPY TECHNOLOGIES MARKET, 2021-2024
  • TABLE 9 IMPORT VOLUME FOR HS CODE 854330, 2019-2023 (UNITS)
  • TABLE 10 EXPORT VOLUME FOR HS CODE 854330, 2019-2023 (UNITS)
  • TABLE 11 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF CONFERENCES & EVENTS
  • TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 CELL THERAPY TECHNOLOGIES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP FOUR END USERS
  • TABLE 18 KEY BUYING CRITERIA FOR CELL THERAPY TECHNOLOGIES PRODUCTS, BY END USER
  • TABLE 19 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 20 CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 21 NORTH AMERICA: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 22 EUROPE: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 23 ASIA PACIFIC: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 24 LATIN AMERICA: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 25 MIDDLE EAST: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 26 GCC COUNTRIES: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 27 CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 28 CELL THERAPY EQUIPMENT MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 29 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 30 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 31 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 32 LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 33 MIDDLE EAST: CELL THERAPY EQUIPMENT MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 34 GCC COUNTRIES: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 35 CELL PROCESSING EQUIPMENT MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 36 NORTH AMERICA: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 37 EUROPE: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 38 ASIA PACIFIC: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 39 LATIN AMERICA: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 40 MIDDLE EAST: CELL PROCESSING EQUIPMENT MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 41 GCC COUNTRIES: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 42 SINGLE-USE EQUIPMENT MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 43 NORTH AMERICA: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 44 EUROPE: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 45 ASIA PACIFIC: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 46 LATIN AMERICA: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 47 MIDDLE EAST: SINGLE-USE EQUIPMENT MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 48 GCC COUNTRIES: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 49 OTHER CELL THERAPY EQUIPMENT MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 50 NORTH AMERICA: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 51 EUROPE: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 52 ASIA PACIFIC: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 53 LATIN AMERICA: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 54 MIDDLE EAST: OTHER CELL THERAPY EQUIPMENT MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 55 GCC COUNTRIES: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 56 CELL THERAPY SYSTEMS & SOFTWARE, BY COMPANY
  • TABLE 57 CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 58 NORTH AMERICA: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 59 EUROPE: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 60 ASIA PACIFIC: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 61 LATIN AMERICA: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 62 MIDDLE EAST: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 63 GCC COUNTRIES: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 64 CELL CULTURE VESSELS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 65 NORTH AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 66 EUROPE: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 67 ASIA PACIFIC: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 68 LATIN AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 69 MIDDLE EAST: CELL CULTURE VESSELS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 70 GCC COUNTRIES: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 71 CELL ENGINEERING PRODUCTS OFFERED, BY COMPANY
  • TABLE 72 CELL ENGINEERING PRODUCTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 73 NORTH AMERICA: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 74 EUROPE: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 75 ASIA PACIFIC: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 76 LATIN AMERICA: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 77 MIDDLE EAST: CELL ENGINEERING PRODUCTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 78 GCC COUNTRIES: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 79 OTHER CELL THERAPY PRODUCTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 80 NORTH AMERICA: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 81 EUROPE: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 82 ASIA PACIFIC: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 83 LATIN AMERICA: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 84 MIDDLE EAST: OTHER CELL THERAPY PRODUCTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 85 GCC COUNTRIES: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 86 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 87 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 88 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 89 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 90 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 91 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 92 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 93 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 94 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 95 CELL THERAPY TECHNOLOGIES MARKET FOR CELL EXPANSION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 96 CELL THERAPY TECHNOLOGIES MARKET FOR CELL EXPANSION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 97 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL EXPANSION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 98 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL EXPANSION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 99 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL EXPANSION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 100 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL EXPANSION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 101 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL EXPANSION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 102 CELL THERAPY TECHNOLOGIES MARKET FOR CELL ISOLATION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 103 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ISOLATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 104 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ISOLATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 105 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ISOLATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 106 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ISOLATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 107 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ISOLATION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 108 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ISOLATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 109 CELL THERAPY TECHNOLOGIES MARKET FOR CELL CHARACTERIZATION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 110 CELL THERAPY TECHNOLOGIES MARKET FOR CELL CHARACTERIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 111 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CHARACTERIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 112 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CHARACTERIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 113 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CHARACTERIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 114 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CHARACTERIZATION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 115 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CHARACTERIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 116 CELL THERAPY TECHNOLOGIES MARKET FOR CELL COLLECTION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 117 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL COLLECTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 118 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL COLLECTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 119 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL COLLECTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 120 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL COLLECTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 121 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL COLLECTION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 122 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL COLLECTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 123 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 124 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 125 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 126 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 127 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 128 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 129 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 130 CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 131 CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 132 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 133 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 134 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 135 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 136 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 137 CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 138 CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 139 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 140 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 141 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 142 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 143 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 144 CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 145 CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 146 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 147 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 148 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 149 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 150 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 151 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 152 T-CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 153 NORTH AMERICA: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 154 EUROPE: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 155 ASIA PACIFIC: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 156 LATIN AMERICA: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 157 MIDDLE EAST: T-CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 158 GCC COUNTRIES: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 159 STEM CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 160 NORTH AMERICA: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 161 EUROPE: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 162 ASIA PACIFIC: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 163 LATIN AMERICA: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 164 MIDDLE EAST: STEM CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 165 GCC COUNTRIES: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 166 OTHER CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 167 NORTH AMERICA: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 168 EUROPE: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 169 ASIA PACIFIC: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 170 LATIN AMERICA: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 171 MIDDLE EAST: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 172 GCC COUNTRIES: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 173 CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 174 CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 175 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 176 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 177 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 178 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 179 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 180 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 181 CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 182 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 183 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 184 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 185 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 186 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 187 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 188 CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 189 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 190 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 191 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 192 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 193 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 194 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 195 CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 196 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 197 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 198 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 199 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 200 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 201 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 202 CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 203 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 204 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 205 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 206 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 207 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 208 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 209 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 210 CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 211 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 212 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 213 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 214 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 215 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 216 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 217 CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 218 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 219 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 220 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 221 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 222 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 223 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 224 CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 225 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 226 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 227 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 228 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 229 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 230 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 231 CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 232 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 233 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 234 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 235 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 236 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 237 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 238 CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 239 NORTH AMERICA: KEY MACROINDICATORS
  • TABLE 240 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 241 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 242 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 243 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 244 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 245 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 246 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 247 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 248 US: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 249 US: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 250 US: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 251 US: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 252 US: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 253 US: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 254 US: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 255 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 256 CANADA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 257 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 258 CANADA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 259 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 260 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 261 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 262 EUROPE: KEY MACROINDICATORS
  • TABLE 263 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 264 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 265 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 266 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 267 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 268 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 269 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 270 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 271 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 272 GERMANY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 273 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 274 GERMANY: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 275 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 276 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 277 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 278 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 279 UK: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 280 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 281 UK: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 282 UK: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 283 UK: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 284 UK: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 285 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 286 FRANCE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 287 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 288 FRANCE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 289 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 290 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 291 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 292 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 293 ITALY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 294 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 295 ITALY: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 296 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 297 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 298 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 299 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 300 SPAIN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 301 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 302 SPAIN: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 303 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 304 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 305 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 306 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 307 REST OF EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 308 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 309 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 310 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 311 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 312 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 313 ASIA PACIFIC: KEY MACROINDICATORS
  • TABLE 314 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 315 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 316 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 317 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 318 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 319 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 320 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 321 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 322 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 323 CHINA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 324 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 325 CHINA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 326 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 327 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 328 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 329 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 330 JAPAN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 331 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 332 JAPAN: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 333 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 334 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 335 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 336 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 337 INDIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 338 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 339 INDIA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 340 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 341 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 342 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 343 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 344 AUSTRALIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 345 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 346 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 347 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 348 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 349 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 350 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 351 SOUTH KOREA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 352 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 353 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 354 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 355 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 356 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 357 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 358 REST OF ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 359 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 360 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 361 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 362 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 363 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 364 LATIN AMERICA: KEY MACROINDICATORS
  • TABLE 365 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 366 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 367 LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 368 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 369 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 370 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 371 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 372 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 373 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 374 BRAZIL: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 375 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 376 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 377 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 378 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 379 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 380 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 381 MEXICO: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 382 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 383 MEXICO: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 384 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 385 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 386 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 387 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 388 REST OF LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 389 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 390 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 391 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 392 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 393 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 394 MIDDLE EAST: KEY MACROINDICATORS
  • TABLE 395 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 396 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 397 MIDDLE EAST: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 398 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 399 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 400 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 401 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 402 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 403 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 404 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 405 GCC COUNTRIES: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 406 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 407 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 408 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 409 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 410 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 411 SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 412 SAUDI ARABIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 413 SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 414 SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 415 SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 416 SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 417 SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 418 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 419 UAE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 420 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 421 UAE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 422 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 423 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 424 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 425 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 426 REST OF GCC COUNTRIES: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 427 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 428 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 429 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 430 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 431 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 432 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 433 REST OF MIDDLE EAST: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 434 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 435 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 436 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 437 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 438 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 439 AFRICA: KEY MACROINDICATORS
  • TABLE 440 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 441 AFRICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 442 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022-2029 (USD MILLION)
  • TABLE 443 AFRICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 444 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022-2029 (USD MILLION)
  • TABLE 445 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 446 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 447 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES, 2021-2023
  • TABLE 448 CELL THERAPY TECHNOLOGIES MARKET: DEGREE OF COMPETITION
  • TABLE 449 CELL THERAPY TECHNOLOGIES MARKET: REGION FOOTPRINT
  • TABLE 450 CELL THERAPY TECHNOLOGIES MARKET: PRODUCT FOOTPRINT
  • TABLE 451 CELL THERAPY TECHNOLOGIES MARKET: PROCESS FOOTPRINT
  • TABLE 452 CELL THERAPY TECHNOLOGIES MARKET: CELL TYPE FOOTPRINT
  • TABLE 453 CELL THERAPY TECHNOLOGIES MARKET: APPLICATION FOOTPRINT
  • TABLE 454 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 455 CELL THERAPY TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
  • TABLE 456 CELL THERAPY TECHNOLOGIES MARKET: PRODUCT LAUNCHES, JANUARY 2021-NOVEMBER 2024
  • TABLE 457 CELL THERAPY TECHNOLOGIES MARKET: DEALS, JANUARY 2021- NOVEMBER 2024
  • TABLE 458 CELL THERAPY TECHNOLOGIES MARKET: EXPANSIONS, JANUARY 2021- NOVEMBER 2024
  • TABLE 459 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 460 DANAHER CORPORATION: PRODUCTS OFFERED
  • TABLE 461 DANAHER CORPORATION: PRODUCT LAUNCHES, JANUARY 2021- OCTOBER 2024
  • TABLE 462 DANAHER CORPORATION: DEALS, JANUARY 2021- OCTOBER 2024
  • TABLE 463 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021- OCTOBER 2024
  • TABLE 464 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 465 MERCK KGAA: PRODUCTS OFFERED
  • TABLE 466 MERCK KGAA: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 467 MERCK KGAA: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 468 THERMO FISHER SCIENTIFIC INC: COMPANY OVERVIEW
  • TABLE 469 THERMO FISHER SCIENTIFIC INC: PRODUCTS OFFERED
  • TABLE 470 THERMO FISHER SCIENTIFIC INC: PRODUCT LAUNCHES, JANUARY 2021-SEPTEMBER 2024
  • TABLE 471 THERMO FISHER SCIENTIFIC INC: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 472 THERMO FISHER SCIENTIFIC INC: EXPANSIONS, JANUARY 2021-OCTOBER 2024
  • TABLE 473 LONZA: COMPANY OVERVIEW
  • TABLE 474 LONZA: PRODUCTS OFFERED
  • TABLE 475 LONZA: PRODUCT LAUNCHES, JANUARY 2021- OCTOBER 2024
  • TABLE 476 LONZA: DEALS, JANUARY 2021- OCTOBER 2024
  • TABLE 477 SARTORIUS: COMPANY OVERVIEW
  • TABLE 478 SARTORIUS AG: PRODUCTS OFFERED
  • TABLE 479 SARTORIUS AG: PRODUCT LAUNCHES, JANUARY 2021-OCTOBER 2024
  • TABLE 480 SARTORIUS AG: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 481 SARTORIUS AG: EXPANSIONS, JANUARY 2021- OCTOBER 2024
  • TABLE 482 AGILENT TECHNOLOGIES: COMPANY OVERVIEW
  • TABLE 483 AGILENT TECHNOLOGIES: PRODUCTS OFFERED
  • TABLE 484 AGILENT TECHNOLOGIES: PRODUCT LAUNCHES, JANUARY 2021-OCTOBER 2024
  • TABLE 485 AGILENT TECHNOLOGIES: DEALS, JANUARY 2021- OCTOBER 2024
  • TABLE 486 AVANTOR: COMPANY OVERVIEW
  • TABLE 487 AVANTOR: PRODUCTS OFFERED
  • TABLE 488 AVANTOR: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 489 FRESENIUS: COMPANY OVERVIEW
  • TABLE 490 FRESENIUS: PRODUCTS OFFERED
  • TABLE 491 FRESENIUS: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 492 BD: COMPANY OVERVIEW
  • TABLE 493 BD: PRODUCTS OFFERED
  • TABLE 494 BD: PRODUCT LAUNCHES, JANUARY 2021- OCTOBER 2024
  • TABLE 495 CORNING INCORPORATED: COMPANY OVERVIEW
  • TABLE 496 CORNING INCORPORATED: PRODUCTS OFFERED
  • TABLE 497 TERUMO CORPORATION: COMPANY OVERVIEW
  • TABLE 498 TERUMO CORPORATION: PRODUCTS OFFERED
  • TABLE 499 TERUMO CORPORATION: PRODUCT LAUNCHES, JANUARY 2021-OCTOBER 2024
  • TABLE 500 TERUMO CORPORATION: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 501 TERUMO CORPORATION: EXPANSIONS, JANUARY 2021-OCTOBER 2024
  • TABLE 502 BIO-TECHNE: COMPANY OVERVIEW
  • TABLE 503 BIO-TECHNE: PRODUCTS OFFERED
  • TABLE 504 BIO-TECHNE: PRODUCT LAUNCHES, JANUARY 2021-OCTOBER 2024
  • TABLE 505 BIO-TECHNE: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 506 BIO-TECHNE: OTHER DEVELOPMENTS, JANUARY 2021-OCTOBER 2024
  • TABLE 507 GENSCRIPT: COMPANY OVERVIEW
  • TABLE 508 GENSCRIPT: PRODUCTS OFFERED
  • TABLE 509 GENSCRIPT: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 510 MAXCYTE: COMPANY OVERVIEW
  • TABLE 511 MAXCYTE: PRODUCTS OFFERED
  • TABLE 512 MAXCYTE: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 513 STEMCELL TECHNOLOGIES: COMPANY OVERVIEW
  • TABLE 514 STEMCELL TECHNOLOGIES: PRODUCTS OFFERED
  • TABLE 515 STEMCELL TECHNOLOGIES: PRODUCT LAUNCHES, JANUARY 2021- OCTOBER 2024
  • TABLE 516 STEMCELL TECHNOLOGIES: DEALS, JANUARY 2021-OCTOBER 2024

List of Figures

  • FIGURE 1 CELL THERAPY TECHNOLOGIES MARKET SEGMENTATION AND REGIONAL SCOPE
  • FIGURE 2 CELL THERAPY TECHNOLOGIES MARKET: RESEARCH DESIGN
  • FIGURE 3 CELL THERAPY TECHNOLOGIES MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
  • FIGURE 4 CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
  • FIGURE 5 MARKET SIZE ESTIMATION APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
  • FIGURE 6 ILLUSTRATIVE EXAMPLE OF DANAHER CORPORATION: REVENUE SHARE ANALYSIS (2023)
  • FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 9 CELL THERAPY TECHNOLOGIES MARKET: CAGR PROJECTIONS
  • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • FIGURE 11 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 GEOGRAPHICAL SNAPSHOT OF CELL THERAPY TECHNOLOGIES MARKET (2024-2029)
  • FIGURE 17 INCREASED FUNDING & INVESTMENT IN CELL THERAPY AND ADVANCEMENTS IN GENE EDITING TECHNOLOGIES TO DRIVE MARKET
  • FIGURE 18 US ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • FIGURE 19 MEDIA, SERA, AND REAGENTS TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 20 APAC COUNTRIES TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 21 CELL THERAPY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 22 CELL THERAPY TECHNOLOGIES MARKET: ECOSYSTEM
  • FIGURE 23 AVERAGE SELLING PRICE TREND OF CELL THERAPY EQUIPMENT, 2024 (USD THOUSAND)
  • FIGURE 24 CELL THERAPY TECHNOLOGIES MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 25 CELL THERAPY TECHNOLOGIES MARKET: OVERVIEW OF PATENTING ACTIVITY
  • FIGURE 26 CELL THERAPY TECHNOLOGIES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
  • FIGURE 28 KEY BUYING CRITERIA FOR TOP FOUR END USERS
  • FIGURE 29 GOVERNMENT FUNDING FOR R&D FROM 2019-2024
  • FIGURE 30 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 31 CELL THERAPY TECHNOLOGIES MARKET: IMPACT OF AI
  • FIGURE 32 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT
  • FIGURE 33 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT
  • FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET, 2021-2023
  • FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET, 2023
  • FIGURE 36 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 37 CELL THERAPY TECHNOLOGIES MARKET: COMPANY FOOTPRINT
  • FIGURE 38 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 39 EV/EBITDA OF KEY VENDORS
  • FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 41 CELL THERAPY TECHNOLOGIES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT
  • FIGURE 44 THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT
  • FIGURE 45 LONZA: COMPANY SNAPSHOT
  • FIGURE 46 SARTORIUS AG: COMPANY SNAPSHOT
  • FIGURE 47 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT
  • FIGURE 48 AVANTOR: COMPANY SNAPSHOT
  • FIGURE 49 FRESENIUS: COMPANY SNAPSHOT
  • FIGURE 50 BD: COMPANY SNAPSHOT
  • FIGURE 51 CORNING INCORPORATED: COMPANY SNAPSHOT
  • FIGURE 52 TERUMO CORPORATION: COMPANY SNAPSHOT
  • FIGURE 53 BIO-TECHNE: COMPANY SNAPSHOT
  • FIGURE 54 GENSCRIPT: COMPANY SNAPSHOT
  • FIGURE 55 MAXCYTE: COMPANY SNAPSHOT